COVID-19 and the need for stringent rules on data sharing

Main Article Content

Kewal Krishan
Tanuj Kanchan


COVID-19, Retractions, Publication Frauds, Data sharing, Publication ethics


This communication refers to the retractions of the two high profile COVID-19 papers of the top medical journals when the data analytics company declined to share the raw data of the papers. In this commentary, we emphasize that it is very pertinent for the journals to mandatorily ask the authors for sharing of the primary data. This will ensure data integrity and transparency of the research findings, and help in negating the publication frauds.


Download data is not yet available.


Metrics Loading ...
Abstract 49 | PDF Downloads 13


1. Mehra MR, Desai SS, Kuy S, Henry TD, Patel AN. Cardiovascular disease, drug therapy, and mortality in Covid-19. N Engl J Med 2020;382:e102-e102. DOI: 10.1056/NEJMoa2007621 (Retracted)
2. Mehra MR, Desai SS, Ruschitzka F, Patel AN. Hydroxychloroquine or chloroquine with or without a macrolide for treatment of COVID-19: a multinational registry analysis, Lancet 2020, DOI: 10.1016/S0140-6736(20)31180-6 (Retracted)
3. Ledford H, Van Noorden R. High profile coronavirus retractions raise concerns about data oversight. Nature 200, 582, 488, doi: 10.1038/d41586-020-01695-w
4. Yeo-The NSL. Tang BL. An alarming retraction rate for scientific publications on Coronavirus Disease 2019 (COVID-19). Account Res 2020, doi: 10.1080/08989621.2020.1782203